

Ref: FOI/CAD/ID 3225

Please reply to:
FOI Administrator
Trust Management
Service Centre
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

27 May 2016

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis and MRI.

Number of patients with an annual review in the last 12 months and number of patients with an MRI in the last 12 months being treated with the following products:

- *Tysabri*
- *Gilenya*
- *Interferon beta 1a*
- *Interferon beta 1b*
- *Copaxone*
- *Lemtrada*
- *Tecfidera*
- *Aubagio*
- *Plegridy*

I would also like to request the following information on patient numbers:

- *Number of new MS diagnoses*
- *Number of patients who have had a relapse in the above month*
- *Number of relapse events in the above month*

I would like this information for the period March 2015 to February 2016, broken down by month

Tysabri, Gilenya and Lemtrada - patients are seen at Kings College Hospital.

Annual review by a MS nurse only

- Interferon 1 a- Rebif and Avonex - total of 72 patients. Out of all of these patients 69 approx. have had an annual review by a MS nurse. 3 patients have been lost to the system despite contact. Tunbridge Wells and Maidstone
- Interferon 1 B - 13 patients. Tunbridge Wells and Maidstone.
- Copaxone: 46 patients for Tunbridge Wells and Maidstone

- Augabio patients - 3 patients for Maidstone areas. Bloods monitored every 2 weeks. 1 patient started in Sept 2015 and 2 started in January 2016.
- Plegridy - 1 patient only for Maidstone and Tunbridge Wells
- Tecfidera- 36 patients for Maidstone and Tunbridge Wells. Monitored every 3 months.

•
All of the above patients are reviewed annually.

MRI

Tecfidera patients- 2 for Maidstone areas - 1 in Dec 2015 and 1 in Feb 2016.

For Maidstone areas- Newly diagnosed:

- 2 - March 2015
- 0- April 2015
- 2 - May 2015
- 1 - June 2015
- 2 -July 2015
- 1- August 2015
- 4 - Sept 2015
- 0 - Oct 2015
- 1- Nov 2015
- 0- Dec 2015
- 3- Jan 2016
- 2- Feb 2016

•
The figures above are only for newly diagnosed in the Maidstone areas only, excludes Tunbridge Wells. This also excludes any other MS referrals. Other MS referrals for Maidstone: 33 patients that have been referred via a GP or consultant Neurologist.

Tunbridge Wells area – Newly diagnosed:

Copaxone - 18 patients

Rebif - 10 patients

Avonex - 10 patients

Betaferon - 4 patients

Tecfidera - 14 patients

All Tecfidera patients have a form filled in for yearly MRI

We do not use Lemtrada or Tysabri patients are followed up in London. All patients are started on Gilenya in London

Relapses:

These figures are not held electronically and the Trust has estimated that it will cost more than the appropriate limit to consider this part of your request. The appropriate limit is specified in regulations and represents the estimated

cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with this part of your request and we will not be processing this part of your request further.